Objectives: To prove whether intramyocardial transplantation of combined skeletal myoblasts (SM) and mononuclear bone marrow stem cells is superior to the isolated transplantation of these cell types after myocardial infarction in rats. Methods: In 67 male Fischer rats myocardial infarction was induced by direct ligature of the LAD. Seven days postinfarction baseline echocardiography and intramyocardial cell transplantation were performed. Via lateral thoracotomy 200 ml containing either 10 7 SMs or 10 7 bone marrow-derived mononuclear cells (BM-MNC) or a combination of 5 £ 10 6 of both cell types (MB) were injected in 10 -15 sites in and around the infarct zone. In controls (C) 200 ml of cell-free medium were injected in the same manner. Before injection both cell types were stained using a fluorescent cell linker kit (PKH, Sigma). In addition, SMs were transfected with green fluorescent protein. Nine weeks postinfarction follow-up echocardiography was performed and animals were sacrificed for further analysis. Results: At baseline echocardiography there was no difference in left ventricular ejection fraction (LVEF; C, SM, BM-MNC, MB: 60.1^3.2, 53.3^10.2, 53.1^8.7, 49^9.0%) and left ventricular end diastolic diameter (LVEDD; C, SM, BM-MNC, MB: 6.5^0.8, 5.17^0.8, 5.77^1.4, 6.25^0.8 mm) between the different therapeutic groups. Eight weeks after cell transplantation LVEDD was significantly increased in all animals except those that received a combination of myoblasts and bone marrow stem cells (MB; C, SM, BM-MNC, MB: 7.7^0.6 mm, P ¼ 0:001; 7.7^1.5 mm, P , 0:001; 7.7^1.1 mm, P ¼ 0:005; 6.6^1.7 mm, P ¼ 0:397). At the same time LVEF decreased significantly in the control group (C), stayed unchanged in animals that received bone marrow stem cells (BM-MNC) and increased in animals that received myoblasts (SM) and a combination of both cell types (MB; C, SM, BM-MNC, MB: 45.3^7.0%, P ¼ 0:05; 63.9^15.4%, P ¼ 0:044; 54.3^6.3%, P ¼ 0:607; 63.0^11.5%, P ¼ 0:039). Conclusions: The present data show that the concept of combining SMs with bone marrow-derived stem cells may be of clinical relevance by merging the beneficial effects of each cell line and potentially reducing the required cell quantity. Further studies are required to identify the exact mechanisms underlying this synergy and to allow full exploitation of its therapeutic potential. q
Introduction
The adult heart lacks the potential of effective regeneration. Instead of tissue recovery the infarcted myocardium is transformed into a non-contractile fibrous scar. The following remodelling process leads to expansion of the initial infarct area and dilatation of the left ventricular lumen [1] . As one novel therapeutic option attempting to stop or even reverse the process of postinfarction remodelling and restoring left ventricular function, cellular cardiomyoplasty has been proposed and opened new perspectives for the treatment of ischemic heart disease [2] . In a number of myocardial injury models, different cell lines proved the potential to regenerate viable tissue after being transplanted into the infarcted heart [2 -6] . Among those, skeletal myoblasts (SM) improved myocardial performance in vitro and in vivo, either delivered to the injured myocardium by intramural implantation or arterial injection [2,7 -10] . There is evidence that the cardiac environment is permissive for myogenic differentiation and influences the developmental program of implanted myoblasts, improving their ability to assist myocardial performance [7, 8] . These convincing preclinical data led to the first application in a clinical setting by Menasché and coworkers reported in 2001 [11] and the conductance of phase I clinical trials [12, 13] . Corresponding to preclinical data, the results of these trials suggest a contribution of engrafted myotubes to the contractile function of treated areas.
As a second potential candidate for cellular cardiomyoplasty bone marrow-derived stem cells (BMC) have been successfully transplanted in several experimental settings [14, 15] . One major advantage of bone marrow stem cells over SMs may be their pluripotentiality. BMC are suggested to acquire the phenotypic characteristics of their host tissue and to differentiate into cardiomyocytes and endothelial cells following engraftment into myocardium [6,16 -18] . In a recent experimental trial, the implantation of total unpurified bone marrow into injured myocardium was associated with cardiomyogenic and endothelial transdifferentiation [19] . Results of first clinical trials suggest that injected bone marrow-derived mononuclear cells (BM-MNC) cause an improvement of myocardial blood flow and an associated enhancement of regional and global left ventricular function in treated patients [20, 21] . This effect has been seen in areas of hibernating myocardium and is therefore suggested to be primarily related to an induction of angiogenesis.
Corresponding to the different cell types, both therapeutic approaches have to deal with different limitations. In the case of SM transplantation the total myoblast survival in the human setting was calculated to be below 1%. This finding was discussed to be caused by the lack of a vascular bed allowing sufficient tissue perfusion [13] . In BM-MNC transplantation the number of cells transdifferentiated to cardiomyocytes was very small, raising concern over the functional efficacy of isolated BMC transplantation [19] . To overcome the individual limitations of both therapeutic options, the isolated transplantation of SMs and of bone marrow-derived cells, a combination of these two cell types may be a new therapeutic approach. The aim of the present study was therefore to prove whether intramyocardial transplantation of combined SMs and mononuclear bone marrow stem cells in a rat ischemic myocardial injury model is superior to the isolated transplantation of these cell types.
Materials and methods

Isolation and expansion of skeletal myoblasts and bone marrow stem cells
Primary SMs were isolated from a male F344 Fischer rat (6 weeks of age). After intraperitoneal administration of ketamine (50 mg/100 g) and xylazine (1 mg/100 g) hind limb muscles (0.5 -1.0 g) were dissected free from connective tissues, and minced into pieces of approximately 1 mm 3 . Muscle samples were enzymatically dissociated according to the cell dispersion technique described by Blau and Webster. Single satellite cells in suspension were manually collected with a micropipette under microscope control and transferred into the cell culture with 96-well plates. The cells were cultured in growth media and maintained in a proliferating state. Desmin was used as a marker to identify clones of myoblasts (Fig. 1A) . To confirm the ability to differentiate, desmin-positive mononucleated myoblasts were cultured in differentiation media. Under these conditions myoblasts fused into multinucleated myotubes (Fig. 1B) . After 1 week in differentiation medium spontaneous contractions of the myotubes were observed. Electrophysiologic analysis revealed myoblast characteristic Ba 2þ currents through T-type calcium channels in myoblasts (Fig. 1C , left panel) with corresponding currentvoltage relationship (Fig. 1C, right panel) .
Before intramyocardial injection, cells were labelled using a fluorescent cell linker kit (PKH26-GL, SigmaAldrich Co., Vienna, Austria) following the instructions of the manufacturer.
Bone marrow stem cells were isolated from male F344 Fischer rats. After intraperitoneal administration of ketamine (50 mg/100 g) and xylazine (1 mg/100 g) both femurs were dissected and bone marrow was flushed with 5 ml medium using a 21 G needle. Cells were washed twice with RPMI Medium. Mononuclear cells were isolated by Percoll gradient (Lymphoprep, Nycomed). In rodents, bone marrow mononuclear cells comprise 4-17% CD34 þ stem cells [23] . In humans, co-expression of VEGF-R2, CD34 and AC133 is a characteristic feature of endothelial progenitor cells (EPC) [24] . However, no data are currently available on the frequency of EPC in rat bone marrow mononuclear cells. Before transplantation, cells were labelled with a green fluorescent cell linker kit (PKH2-GL, Sigma-Aldrich Co., Vienna, Austria) following the instructions of the manufacturer.
Myocardial infarction and cell transplantation
Myocardial infarction was induced following a standardized protocol: 67 male F344 Fischer rats were anaesthetised (ketamine 10 mg/100 g and xylazine 1 mg/100 g intraperitoneally), placed in a supine position on a temperature-controlled plate (37 8C) and tracheally ventilated with a small animal Harvard respirator (Harvard Apparatus Rodent Ventilator Mod. 40-1003, Harvard Apparatus Inc., Millis, MA). The heart was exposed through a 2 cm left lateral thoracotomy and the left coronary artery was ligated with a Prolene w 7/0 suture under the distal portion of the left atrial appendix. Correct position of the ligation was assessed by colour change of the ischemic area, regional wall motion and electrocardiographic (ECG) recording. After haemostasis was achieved, the muscle layer and skin incision was closed with Vicryl w 3/0 running sutures after drainage of the left thoracic cavity with a 16 G silicon tube. All animals were monitored for 4 h postoperatively.
One week after myocardial infarction, all animals ðn ¼ 52Þ underwent a second thoracotomy following the same protocol as described above. The heart was exposed via the same intercostal space as in the first operation and the infarcted area of the lateral left ventricular wall was clearly identified. Animals were now divided into four subgroups: the myoblast group ðn ¼ 14Þ; the bone marrow group ðn ¼ 14Þ; the combined therapy group ðn ¼ 14Þ and the control group ðn ¼ 10Þ: In the myoblast group 10 7 homologous SMs were injected into 15 microdepots of 10 ml each in the centre and border zone of myocardial infarction. Injections were performed using a modified 24 G needle (Becton Dickinson, Helsingborg, Sweden) covered with a rubber tube allowing only a 1.5 mm puncture to avoid intracavitary injection. The needle was mounted on a modified 1 ml syringe that was connected via a polyethylene tube (outer diameter, 2.0 mm; inner diameter, 1.0 mm; Becton Dickinson, Helsingborg, Sweden) to a time gated pneumatic pump (PV 830, Pneumatic PicoPump, World Precision Instruments, Sarasota, FL, USA). The picopump was adjusted to a pressure of 30 psi at a gated impulse duration of 500-700 ms. Under these conditions a volume of 10 ml was injected intramyocardially with each pressure impulse. Cell death related to this procedure (shear force in needle and syringe) was calculated to be below 5% in a separated experiment. After accurate haemostasis the chest was closed and drained. In the bone marrow group 15 depots of 10 ml each containing 10 7 homologous bone marrow mononuclear cells were injected. In the combined treatment group, 15 depots of 10 ml containing 5 £ 10 6 homologous SMs as well as 5 £ 10 6 homologous bone marrow stem cells (therefore the sum of 10 7 cells, corresponding to the other cell-treated study groups) were injected following the same protocol as in the myoblast group. In the control group 15 depots of 10 ml empty culture medium (DMEM 31885-023, GIBCO) were injected following the same protocol. After closure of the chest all animals were monitored for 4 h and underwent the same postoperative routine.
Functional assessment
Left ventricular function was assessed by two-dimensional echocardiography 1 week after myocardial infarction (at baseline, before cell transplantation) and 8 weeks after cell transplantation. Under general anaesthesia with ketamine (0.1 mg/100 g) the chest was shaved and a layer of acoustic coupling gel was applied. Two-dimensional and M-mode measurements were performed with a commercially available 15 MHz linear-array transducer system (AcuNav, Acuson Corp., Mountain View, CA). Parasternal long axis views were recorded and left ventricular dimensions and volumes were calculated according to standard formulas. All measurements were performed by two experienced investigators who were blinded to the treatment group.
Histology and immune histochemistry
Within 3 days after follow-up echocardiography all animals were sacrificed with an overdose of ketamine and xylazine and hearts were harvested and cryopreserved for further histological analysis. The ventricles were crosssectioned into three sections. From each section 8 mm slides were prepared using a cryostat and standard histological studies were performed with haematoxylin and eosin staining. The transplanted myoblasts were identified by fluorescence. For von Willebrand Factor (vWF) staining cryosections were mounted on glass slides, rinsed in PBS and fixed in 100% methanol at 2 20 8C for 5 min. All further incubations were carried out at room temperature and all rinses and dilutions were performed with a blocking solution consisting of 2% BSA and 0.5% Triton X-100 in PBS. An initial blocking step was performed with this solution for 30 min. An antibody to anti-vWF (F3520, Sigma) with a dilution of 1:200 was applied for 1 h. After rinsing a peroxidase-conjugated anti-rabbit IgG (A0545, Sigma) with a working dilution of 1:500 was applied for 30 min. The sections were rinsed and stained with AEC chromogen (3-amino-9-ethylcarbazole in N,N-dimethylformamide; IMMH5, Sigma). Endogenous peroxide was quenched with 3% hydrogen peroxide. The number of capillaries was counted in the scar tissue of all four animal groups using a standard light microscope at a 400 £ magnification. Ten high-power fields in each scar were randomly selected, and the number of capillaries in each was averaged and expressed as the number of capillary vessels per high power field (0.2 mm 2 ). Myoblast graft size was measured in five randomly selected areas within each infarction scar of myoblast-treated animals at 40 £ magnification. Assuming an elliptical graft shape, the graft area was calculated as area ¼ length/2 £ width/2 £ .
Data analysis
Statistical analysis was performed using SPSS 9.0 for windows. In the following, data are expressed as meanŝ tandard deviation. Comparisons of continuous variables among animal groups were studied by a one-way ANOVA. Longitudinal studies comparing data within each group were achieved by the use of paired t-tests. A value of P , 0:05 after Bonferroni correction was considered significant.
Animal care
This study was approved by the Animal Care Commission of the University of Innsbruck and by the Ministry of Science, Republic of Austria. Care of animals was in accordance with the 'Guide for the Care and use of Laboratory Animals' (NIH publication 85-123, revised 1985).
Results
Functional assessment
Major functional results are summarized in Fig. 2 . Baseline echocardiography was performed 1 week after myocardial infarction, the day before cell transplantation. There was no significant difference among the different therapeutic groups. Thus left ventricular ejection fraction (LVEF) was 60.1^3.2% in control rats, 53.3^10.2% in the myoblast group, 53.1^8.7% in the bone marrow group and 49.0^9.0% in the group receiving a combination of myoblasts and bone marrow stem cells ðP ¼ 0:259Þ: At the 8 weeks time point after cell transplantation, there was a significant improvement of ejection fraction in the myoblast group (63.9^15.4%, P ¼ 0:044) and in the group that received the combined therapy (63.0^11.5%, P ¼ 0:039), whereas LVEF stayed unchanged in the bone marrow group (54.3^6.3%, P ¼ 0:607) compared to the corresponding values of baseline echocardiography ( Fig. 2A) . Rats of the combined therapy group, receiving both SMs and bone marrow stem cells improved to a greater extent than those receiving SMs alone, however this difference did not reach the level of significance. In the control group a functional decline was noticed at the 8 weeks time point (45.3^7.0%, P ¼ 0:05).
As a marker of left ventricular remodelling, the left ventricular end diastolic diameter (LVEDD) was assessed. At baseline, the LVEDD was 6.5^0.8 mm in control rats, 5.2^0.8 mm in the myoblast group, 5.8^1.4 mm in the bone marrow group and 6.3^0.8 mm in the group receiving a combination of myoblasts and bone marrow stem cells ðP ¼ 0:112Þ: Eight weeks after cell transplantation LVEDD was significantly increased in all animal groups (control group: 7.7^0.6 mm, P ¼ 0:001; myoblast group: 7.7^1.5 mm, P , 0:001; and bone marrow group: 7.7^1.1 mm, P ¼ 0:005) except in the group that received a combination of myoblasts and bone marrow stem cells (6.6^1. In the myoblast group (A) surviving SM differentiated into multinucleated myotubes that had aligned with the cardiac fibre axis in the host myocardium. In the bone marrow group (B) implanted BM-MNCs were found to be partly scattered over the infarcted area and partly staying at the implantation site. In the combined treatment group (C) myotubes and scattered BM-MNCs were found. Fig. 4 . Effects of SMs and BM-MNCs on neovascularisation. Endothelial cells were stained with anti-factor VIII antibody, and vessel numbers were counted. Total numbers of vessels in 10 areas were evaluated in each animal (SM, n ¼ 12; BM-MNCs, n ¼ 9; combined SM and BM-MNC, n ¼ 10; controls, n ¼ 7) as described. Results shown are mean^SEM. *P , 0:05; **P , 0:01: time point a significant increase of diastolic and systolic ventricular septal thickness was found in the control group (1.2^0.2 mm, P ¼ 0:034 and 1.3^0.1 mm, P ¼ 0:006), the bone marrow group (1.1^0.2 mm, P ¼ 0:004 and 1.4^0.3 mm, P ¼ 0:012) and in a more decent form also in the myoblast group (1.1^0.3 mm, P ¼ 0:019 and 1.2^0.3 mm, P ¼ 0:064). In contrast, the group treated with a combination of myoblast and bone marrow stem cells showed no significant change in septal thicknesses (1.0^0.2 mm, P ¼ 0:452 and 1.1^0.2 mm, P ¼ 0:566; Fig. 2C ).
Histology and immune histochemistry
Representative histological slides of transplanted cell depots in the infarcted region of the left ventricular wall 8 weeks after cell transplantation are shown in Fig. 3 . SMs formed multinucleated myotubes in both myoblast-treated groups ( Fig. 3A and C) . These myotubes had aligned with the fibre axis within the host myocardium. Examination of random areas on light microscopy indicated that the diameter of myoblast grafts was larger in the combined treatment group than in the group that received only myoblasts (0.239^0.158 vs. 0.090^0.050 mm 2 , P , 0:001). In the bone marrow group, one part of the transplanted mononuclear cells scattered over the infarcted area of the left ventricle, whereas the second fraction remained at the implantation site (Fig. 3B) . The formation of homogenous grafts as in myoblast-treated animals was not seen in the bone marrow group. In the combined treatment group myotubes and scattered BM-MNCs were found (Fig. 3C) .
Tissue sections were stained for anti-factor VIII to detect endothelial cells (Fig. 4) . Enhanced angiogenesis with a large number of mature capillaries was found in the area surrounding grafted SMs of the myoblast group ( Fig. 4A ; 41.5^14.0; P , 0:001 vs. control group; P ¼ 0:011 vs. bone marrow group) and the combined treatment group (Fig. 3C ; 41.7^7.9; P , 0:001 vs. control group; P ¼ 0:19 vs. bone marrow group). In rats that were only treated with bone marrow stem cells fewer capillaries were counted ( Fig. 4B ; 26.3^11.7; P ¼ 0:042 vs. control group), the control group showed no obvious angiogenesis ( Fig. 3D; 13.2^5.3) . Comparison of fluorescence slides to corresponding sections that have been stained for anti-factor VIII revealed that BM-MNCs partly corresponded to factor VIII-positive cells (36.38^10.28% of fluorescent cells corresponded to VIII positive cells).
Discussion
SMs as well as bone marrow-derived mononuclear stem cells are promising candidates for cell therapy of the injured heart. Both cell types have been successfully transplanted to infarcted myocardium [2,7 -10] . BM-MNCs and SMs have been shown to undergo adaptive changes induced by their host environment and have proven the potential to improve left ventricular function and postinfarction remodelling [6 -8,16 -18] . In recent trials, both cell types have already reached experimental clinical application [12, 13, 20, 21] . However, the mechanisms underlying the positive effects on myocardial performance seem to be as different as the phenotypes of these cell lines. With the engraftment process, SMs are found to differentiate into multinucleated myotubes, providing mechanical support as fatigue-resistant, slow twitch fibres [2, 8] . BM-MNCs containing various kinds of cell lineages, are regarded to regenerate both cardiomyocytes and endothelial cells, adding contractile function and raising myocardial blood flow [17, 19] . The present preclinical study in rats was designed to test the therapeutic effectiveness of a combined transplantation of SMs and BM-MNCs compared to the isolated application of these cell types.
The main findings of this study include that (1) the isolated transplantation of SMs is more effective than the isolated transplantation of BM-MNCs in regard to improving left ventricular function; (2) but not regarding the postinfarction remodelling; (3) the combined transplantation of SMs and BM-MNCs is more effective than the isolated transplantation of these cell types in preventing postinfarction left ventricular dilatation and compensatory left ventricular hypertrophy; (4) the combined transplantation of SMs and BM-MNCs as well as the isolated transplantation of SMs are more effective in inducing angiogenesis than the isolated transplantation of BM-MNCs; (5) in combination with BM-MNCs half of the number of transplanted SMs was as effective in restoring left ventricular function and inducing angiogenesis as in isolated transplantation of SMs (5 £ 10 6 vs. 10 7 ); (6) the engraftment of SMs is more effective in combined transplantation of SMs and BM-MNCs compared to the isolated transplantation of SMs. Thus this study demonstrates that a combination of SMs and BM-MNCs is superior to the isolated transplantation of these cell types. Considering the fact that BM-MNCs cause a dramatically favourable effect on regional blood flow [17] , it is conceivable that myoblast differentiation and engraftment is improved by a combined treatment. The increase in tissue perfusion and salvage may be one mechanism underlying the clear benefit of BM-MNCs on the postinfarction remodelling if combined with SMs. In this study, isolated BM-MNC transplantation lead to an increased angiogenesis compared to the control group and incorporated into capillary vessel walls. However, BM-MNCs were not as effective as isolated and combined SMs in inducing angiogenesis. Native myoblasts are known to secrete vascular endothelial growth factor (VEGF) and to hold the potential to induce angiogenesis and to increase coronary arterial blood flow [25] . As a second potential factor underlying the beneficial effect of BM-MNC transplantation, the broad spectrum of inflammatory cytokines secreted by BM-MNCs such as IL-1b and TNF-a may increase myoblast differentiation and direct the migration within the infarcted area [17, 22] . The finding that the transplantation of isolated BM-MNC without myoblasts had only little effect on the contractile function is likely due to the fact that the pluripotent bone marrow cells able to transdifferentiate into contractile cells comprise only a small fraction of the total bone marrow pool [19] . Prior enrichment of stem cells by means of FACSsorting or magnetic beads before cell transfer might improve the results in terms of a significant improvement of the contractile function, as far higher concentrations of pluripotent stem/progenitor cells within the microenvironment of the infarcted region become achievable.
In conclusion, the present data show that the concept of combining SMs with BMCs may be of clinical relevance by merging the beneficial effects of each cell line and potentially reducing the required cell quantity. Further studies are required to identify the exact mechanisms underlying this synergy and to allow full exploitation of its therapeutic potential.
